Category Archives: Dual/triple agonist

Novo Initiates Zenagamtide CVOT in Obesity; Novo Enters Purchase Agreement for Three Obesity Programs with Kallyope; Health Canada Approves Sandoz Generic Sema

Three cardiometabolic-related news items have been observed: Novo initiated a Ph3 study evaluating zenagamtide for ASCVD (view EUClinicalTrials record); Novo has entered into an asset purchase agreement with Kallyope to acquire three novel obesity drug programs (view LinkedIn post); and Sandoz received Health Canada approval for its generic semaglutide (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Obesity Spotlight Series: Emerging Players to Watch

In the thirteenth installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a brief analysis of the emerging players in the obesity market. While previous editions of the spotlight series focused on the major players competing in the space, there is no shortage of smaller biotechs that could also shape the landscape in years to come. In this spotlight, FENIX highlights 10 smaller obesity players to watch (as well as honorable mentions), assessing their pipeline progress, competitive positioning, and potential attractiveness as future M&A targets.

This content is for Read Less members only.
Already a member? Log in here

Ascendis/Novo Terminate QM Sema Agreement; Novo Cagrisema Switch Study; Dexcom Appoints COO; Arrowhead ARO-DIMER-PA Data; Elvinix/Zealand ZP3022 Licensing Agreement; Lilly Terminates Ph1 Obesity Asset; Medtronic Expands Separation from MiniMed; Tracky Launches 16-Day CGM in India

A series of cardiometabolic-related news items has been observed from Ascendis Pharma, Novo, Dexcom, Arrowhead Pharmaceuticals, Elvinix, Lilly, MiniMed, and Tracky. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo Rebranding; Corbus Topline Ph1b CB1 Data; New Foundayo DTC TV Ads; New Alveus Ph2 Obesity Study; Beta Bionics Patch Pump FDA Clearance; Senseonics Integrates with Beta Bionics’s iLet AID; September CHMP Agenda

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Corbus Pharmaceuticals, Lilly, Alveus Therapeutics, Beta Bionics, Senseonics, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Innovent Initiates Ph1 INHBE China-based Study in Obesity; BioLife Receives Patent for Dissolvable Obesity Medicine; Novo’s Semaglutide Approved for MASH in China

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its Q3M/Q6M SC INHBE (view CT.gov record); BioLife received a US patent for its effervescent oral peptide delivery technology (view press release); and Novo Nordisk’s injectable semaglutide received approval from NMPA for the treatment of F2-F3 MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ascletis FIH Oral Amylin Study; Moonwalk $70M Series B; New Lilly Obesity Asset; Kura Oncology Spins Out Diabetes Business; MannKind Partners for Inhaled GLP-1RA; NodThera Name Change and Topline Ph2 NLRP3i Data

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, Moonwalk Biosciences, Lilly, Kura Oncology/Caspian Therapeutics, MannKind, and NodThera. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7

A series of cardiometabolic-related news items has been observed from Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, MiniMed, and CSPC Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Innovent QW Oral Small Molecule GLP-1RA Study; Mounjaro CVRR Label Expansion; Pfizer China-Based Berobenatide Obesity Study

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its QW oral small-molecule GLP-1RA (view CT.gov record); Lilly received FDA approval for Mounjaro’s CVRR label expansion based on the SURPASS-CVOT study (view press release); and Pfizer initiated a Ph3 berobenatide study in an obese Chinese population (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here